Sign in
Active, not recruitingNo phase

BIOlogics in Severe Nasal POlyposis SurvEy

Key facts

Who runs it
University Hospital, Lille
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
100 people, planned
Started
10 Feb 2022
Expected to end
Jul 2027
Type of study
Observational
Treatments tested
  • Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)
Record updated
29 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval

Who cannot take part

  • Oral corticotherapy in the previous month
  • Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months apart from ongoing biotherapies for severe asthma
  • Hypersensitivity to humanized antibodies
  • Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID
  • Pregnant or breast-feeding women
  • Patient without social coverage

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.

Read full original descriptionShow less

During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.

New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.

Herein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.

Treatments tested

  • Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps
Publications
Record updated
29 April 2026